Valuation : Recordati

Market Cap 10.78B 12.49B 10.11B 9.23B 17.36B 1,191B 17.44B 120B 46.79B 603B 46.88B 45.87B 2,000B P/E 2026 *
21.2x
P/E 2027 * 17.5x
Enterprise Value 12.53B 14.52B 11.75B 10.73B 20.18B 1,385B 20.27B 139B 54.38B 701B 54.49B 53.31B 2,324B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 4.06x
Free-Float
50.46%
Yield 2026 *
2.9%
Yield 2027 * 3.22%
1 day-3.33%
3 months-3.33%
6 months+1.84%
Current year-11.37%
Current year 55.88
Extreme 55.88
60
1 year 55.88
Extreme 55.88
60
3 years 49
Extreme 49
65.44
5 years 36
Extreme 36
65.44
10 years 31.7
Extreme 31.7
65.44
Manager TitleAgeSince
Chief Executive Officer 64 30/11/2021
Director of Finance/CFO 56 31/12/2025
Chief Tech/Sci/R&D Officer 56 30/09/2023
Director TitleAgeSince
Chairman 54 30/11/2021
Chairman 57 11/06/2018
Director/Board Member 53 11/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%-.--% - - 12.56B
-0.13%-5.61%+59.99%+112.16% 1,048B
+0.85%+0.25%+51.61%+61.23% 640B
-1.03%-2.43%+22.79%+74.16% 456B
-1.46%-3.52%+36.60%+38.39% 362B
-0.72%-2.06%+21.34%+37.92% 295B
-1.19%-0.98%+0.79%+12.29% 255B
-1.05%-0.30%+50.16%+68.66% 236B
+0.08%-0.22%-17.16%-53.76% 204B
-2.14%+1.56%+27.88%+89.54% 185B
Average -0.91%-0.72%+28.22%+48.95% 409.07B
Weighted average by Cap. -0.32%-1.92%+37.92%+65.36%

Financials

2026 *2027 *
Net sales 2.79B 3.23B 2.61B 2.39B 4.49B 308B 4.51B 30.98B 12.1B 156B 12.12B 11.86B 517B 3.01B 3.48B 2.82B 2.57B 4.84B 332B 4.86B 33.42B 13.05B 168B 13.07B 12.79B 558B
Net income 566M 655M 530M 484M 911M 62.51B 915M 6.29B 2.45B 31.63B 2.46B 2.41B 105B 672M 779M 630M 576M 1.08B 74.3B 1.09B 7.47B 2.92B 37.59B 2.92B 2.86B 125B
Net Debt 1.75B 2.03B 1.64B 1.5B 2.82B 193B 2.83B 19.45B 7.59B 97.82B 7.61B 7.44B 324B 1.42B 1.65B 1.33B 1.22B 2.29B 157B 2.3B 15.79B 6.17B 79.45B 6.18B 6.04B 264B
Logo Recordati
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (58.7%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (41.3%). Net sales are distributed geographically as follows: Italy (12.6%), Europe (53.7%), America (23.1%), Asia and Oceania (7.8%) and Africa (2.8%).
Employees
4,654
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
52.65EUR
Average target price
59.26EUR
Spread / Average Target
+12.55%

Quarterly revenue - Rate of surprise